TCRX | TScan Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	4.03 - 4.23
52 Week Range	3.73 - 9.69
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	158,870
Average Volume	226,261
Shares Outstanding	53,370,595
Market Cap	219,886,851
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-07-16

Valuation
Profitability
Growth
Health
P/E Ratio	-4.34
Forward P/E Ratio	N/A
EPS	-0.95
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	175
Country	USA
Website	TCRX

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

TCRX's peers: ACHV, ATRA, CGTX, CUE, IMRN, INMB, IPA, ITOS, NBTX, RCUS, VECT, ICVX, APLS, DAWN, ABOS, XFOR, INZY, TFFP, DRMA, PRQR, ANNX, ARWR, TERN, WVE, ERNA, SPRY, COYA

*Chart delayed

Analyzing fundamentals for TCRX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see TCRX Fundamentals page.

Watching at TCRX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on TCRX Technicals page.